• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

周期性癌症筛查中提前期的贝叶斯推断。

Bayesian inference for the lead time in periodic cancer screening.

作者信息

Wu Dongfeng, Rosner Gary L, Broemeling Lyle D

机构信息

Department of Mathematics and Statistics, Mississippi State University, Mississippi State, Mississippi 39762, USA.

出版信息

Biometrics. 2007 Sep;63(3):873-80. doi: 10.1111/j.1541-0420.2006.00732.x.

DOI:10.1111/j.1541-0420.2006.00732.x
PMID:17825017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2020448/
Abstract

This article develops a probability distribution for the lead time in periodic cancer screening examinations. The general aim is to allow statistical inference for a screening program's lead time, the length of time the diagnosis is advanced by screening. The program's lead time is distributed as a mixture of a point mass and a piecewise continuous distribution. Simulation studies using the HIP (Health Insurance Plan for Greater New York) study's data provide estimates of different characteristics of a screening program under different screening frequencies. The components of this mixture represent two aspects of screening's benefit, namely, a reduction in the number of interval cases and the extent by which screening advanced the age of diagnosis. We present estimates of these two measures for participants in a breast cancer screening program. We also provide the mean, mode, variance, and density curve of the program's lead time. The model can provide policy makers with important information regarding the screening period, frequency, and the endpoints that may serve as surrogates for the benefit to women who take part in a periodic screening program. Though the study focuses on breast cancer screening, it is also applicable to other kinds of chronic disease.

摘要

本文针对定期癌症筛查检查中的提前期建立了一种概率分布。总体目标是对筛查计划的提前期进行统计推断,即筛查使诊断提前的时间长度。该计划的提前期分布为一个点质量和一个分段连续分布的混合。使用纽约市健康保险计划(HIP)研究数据进行的模拟研究提供了不同筛查频率下筛查计划不同特征的估计值。这种混合的组成部分代表了筛查益处的两个方面,即减少间隔期病例数以及筛查使诊断年龄提前的程度。我们给出了乳腺癌筛查计划参与者这两项指标的估计值。我们还提供了该计划提前期的均值、众数、方差和密度曲线。该模型可以为政策制定者提供有关筛查周期、频率以及可能作为参与定期筛查计划女性受益替代指标的终点的重要信息。尽管该研究聚焦于乳腺癌筛查,但它也适用于其他类型的慢性病。

相似文献

1
Bayesian inference for the lead time in periodic cancer screening.周期性癌症筛查中提前期的贝叶斯推断。
Biometrics. 2007 Sep;63(3):873-80. doi: 10.1111/j.1541-0420.2006.00732.x.
2
A projection of benefits due to fecal occult blood test for colorectal cancer.粪便潜血试验用于结直肠癌的获益预测。
Cancer Epidemiol. 2009 Oct;33(3-4):212-5. doi: 10.1016/j.canep.2009.08.001. Epub 2009 Sep 4.
3
MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening.周期性筛查中年龄依赖性敏感性和转移概率的最大似然估计及贝叶斯推断
Biometrics. 2005 Dec;61(4):1056-63. doi: 10.1111/j.1541-0420.2005.00361.x.
4
The lead time distribution when lifetime is subject to competing risks in cancer screening.癌症筛查中当生存期存在竞争风险时的提前期分布。
Int J Biostat. 2012;8(1). doi: 10.1515/1557-4679.1363.
5
Sojourn time and lead time projection in lung cancer screening.肺癌筛查中的逗留时间和领先时间预测。
Lung Cancer. 2011 Jun;72(3):322-6. doi: 10.1016/j.lungcan.2010.10.010. Epub 2010 Nov 13.
6
Estimating key parameters in periodic breast cancer screening-application to the Canadian National Breast Screening Study data.估算周期性乳腺癌筛查中的关键参数-应用于加拿大国家乳腺癌筛查研究数据。
Cancer Epidemiol. 2010 Aug;34(4):429-33. doi: 10.1016/j.canep.2010.04.001.
7
Estimating lead time and sensitivity in a screening program without estimating the incidence in the screened group.在不估计筛查组发病率的情况下,估计筛查项目中的领先时间和敏感性。
Biometrics. 1997 Mar;53(1):217-29.
8
Evaluating the age to begin periodic breast cancer screening using data from a few regularly scheduled screenings.利用一些定期筛查的数据评估开始进行乳腺癌定期筛查的年龄。
Biometrics. 1998 Dec;54(4):1569-78.
9
Sensitivity of screening mammography by density and texture: a cohort study from a population-based screening program in Denmark.基于丹麦人群筛查项目的研究:密度和纹理对筛查性乳腺 X 光摄影的敏感性。
Breast Cancer Res. 2019 Oct 17;21(1):111. doi: 10.1186/s13058-019-1203-3.
10
Factors associated with imaging and procedural events used to detect breast cancer after screening mammography.与用于筛查乳腺钼靶检查后检测乳腺癌的影像学和程序性事件相关的因素。
AJR Am J Roentgenol. 2007 Feb;188(2):385-92. doi: 10.2214/AJR.05.1718.

引用本文的文献

1
Evaluating Semi-Markov Processes and Other Epidemiological Time-to-Event Models by Computing Disease Sojourn Density as Partial Differential Equations.通过将疾病停留密度计算为偏微分方程来评估半马尔可夫过程和其他流行病学事件发生时间模型。
Med Decis Making. 2025 Jul;45(5):569-586. doi: 10.1177/0272989X251333398. Epub 2025 May 8.
2
Evaluation of the Slovenian Breast Cancer Screening Programme: Years of Life Gained and Avoided Deaths.斯洛文尼亚乳腺癌筛查项目评估:获得的生命年数与避免的死亡人数
Cancers (Basel). 2025 Feb 22;17(5):742. doi: 10.3390/cancers17050742.
3
When to initiate cancer screening exam?何时开始癌症筛查检查?
Stat Interface. 2022;15(4):503-514. doi: 10.4310/21-sii716. Epub 2022 Mar 4.
4
Estimation of Lead Time via Low-Dose CT in the National Lung Screening Trial.在国家肺癌筛查试验中通过低剂量CT评估提前期
J Healthc Inform Res. 2018 Jun 12;2(4):353-366. doi: 10.1007/s41666-018-0027-8. eCollection 2018 Dec.
5
Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement.评估用于肺癌早期检测的分子生物标志物:生物标志物何时可用于临床?美国胸科学会官方政策声明。
Am J Respir Crit Care Med. 2017 Oct 1;196(7):e15-e29. doi: 10.1164/rccm.201708-1678ST.
6
Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis.伴有门静脉癌栓的晚期肝细胞癌肝切除术后的生存率
World J Gastroenterol. 2015 Jan 7;21(1):246-53. doi: 10.3748/wjg.v21.i1.246.
7
Inferences for the Lead Time in Breast Cancer Screening Trials under a Stable Disease Model.在稳定疾病模型下的乳腺癌筛查试验中的领先时间推断。
Cancers (Basel). 2011 Apr 26;3(2):2131-40. doi: 10.3390/cancers3022131.
8
Bayesian lead time estimation for the Johns Hopkins Lung Project data.贝叶斯 Lead 时间估计在约翰霍普金斯肺计划数据中的应用。
J Epidemiol Glob Health. 2013 Sep;3(3):157-63. doi: 10.1016/j.jegh.2013.05.001. Epub 2013 Jun 14.
9
How does early detection by screening affect disease progression? Modeling estimated benefits in prostate cancer screening.早期筛查如何影响疾病进展?前列腺癌筛查中模型估计的获益。
Med Decis Making. 2011 Jul-Aug;31(4):550-8. doi: 10.1177/0272989X10396717. Epub 2011 Mar 15.
10
Sojourn time and lead time projection in lung cancer screening.肺癌筛查中的逗留时间和领先时间预测。
Lung Cancer. 2011 Jun;72(3):322-6. doi: 10.1016/j.lungcan.2010.10.010. Epub 2010 Nov 13.

本文引用的文献

1
Evaluating markers for the early detection of cancer: overview of study designs and methods.评估癌症早期检测标志物:研究设计与方法概述
Clin Trials. 2006;3(1):43-56. doi: 10.1191/1740774506cn130oa.
2
MLE and Bayesian inference of age-dependent sensitivity and transition probability in periodic screening.周期性筛查中年龄依赖性敏感性和转移概率的最大似然估计及贝叶斯推断
Biometrics. 2005 Dec;61(4):1056-63. doi: 10.1111/j.1541-0420.2005.00361.x.
3
Effect of screening and adjuvant therapy on mortality from breast cancer.筛查与辅助治疗对乳腺癌死亡率的影响。
N Engl J Med. 2005 Oct 27;353(17):1784-92. doi: 10.1056/NEJMoa050518.
4
Using observational data to estimate an upper bound on the reduction in cancer mortality due to periodic screening.利用观察性数据估计定期筛查导致的癌症死亡率降低的上限。
BMC Med Res Methodol. 2003 Mar 6;3:4. doi: 10.1186/1471-2288-3-4.
5
Alternative definitions of comparable case groups and estimates of lead time and benefit time in randomized cancer screening trials.随机癌症筛查试验中可比病例组的替代定义以及领先时间和受益时间的估计。
Stat Med. 2003 Jan 15;22(1):83-111. doi: 10.1002/sim.1331.
6
Estimation of post-lead-time survival under dependence between lead-time and post-lead-time survival.
Stat Med. 1999 Jan 30;18(2):155-62. doi: 10.1002/(sici)1097-0258(19990130)18:2<155::aid-sim12>3.0.co;2-d.
7
Estimating lead time and sensitivity in a screening program without estimating the incidence in the screened group.在不估计筛查组发病率的情况下,估计筛查项目中的领先时间和敏感性。
Biometrics. 1997 Mar;53(1):217-29.
8
Non-parametric estimation of the post-lead-time survival distribution of screen-detected cancer cases.筛查发现的癌症病例的领先时间后生存分布的非参数估计。
Stat Med. 1995 Dec 30;14(24):2715-25. doi: 10.1002/sim.4780142410.
9
A data-analytic approach for estimating lead time and screening benefit based on survival curves in randomized cancer screening trials.一种基于随机癌症筛查试验生存曲线估计提前期和筛查效益的数据分析方法。
Stat Med. 1994;13(5-7):569-86. doi: 10.1002/sim.4780130519.
10
Estimation of the duration of a pre-clinical disease state using screening data.利用筛查数据估算临床前疾病状态的持续时间。
Am J Epidemiol. 1983 Dec;118(6):865-86. doi: 10.1093/oxfordjournals.aje.a113705.